|Bid||46.00 x 1400|
|Ask||0.00 x 4000|
|Day's Range||49.47 - 49.96|
|52 Week Range||41.03 - 58.37|
|PE Ratio (TTM)||20.29|
|Forward Dividend & Yield||1.28 (2.63%)|
|1y Target Est||60.40|
The wind farm's 72 turbines will have a rotor diameter of 167 meters and weigh almost 900 tons each. The facility, located in the Baltic Sea, is set to be in full operation by the end of 2021. Novozymes and Novo Nordisk have signed an agreement to source power from Vattenfall’s Kriegers Flak offshore wind park, the Swedish utility said Friday.
A handful of the world’s biggest drugmakers are canceling or reducing planned price increases in the U.S., following a new California drug pricing transparency law and continued political pressure over pharmaceutical costs. The California law, which began to take effect earlier this year, requires drugmakers to give insurers, governments and drug purchasers advance notice of large price increases, as a way of publicly pressuring pharmaceutical companies to keep prices down. In the past three weeks, Novartis AG, Gilead Sciences Inc., Roche Holding AG and Novo Nordisk A/S sent notices to California health plans rescinding or reducing previously announced price hikes on at least 10 drugs.
In the first quarter, Novo Nordisk’s (NVO) Hemophilia segment generated net revenues of 2.5 billion Danish kroner compared to 2.58 billion Danish kroner in the first quarter of 2017, reflecting ~3.0% YoY (year-over-year) growth.
Novo Nordisk’s (NVO) Victoza generated revenues of 5.99 billion Danish kroner in the first quarter, compared to 5.75 billion Danish kroner in the first quarter of 2017, reflecting ~4.0% YoY (year-over-year) growth.
WallStEquities.com has initiated research reports on the following Biotechnology stocks: Nabriva Therapeutics PLC (NASDAQ: NBRV), Neurocrine Biosciences Inc. (NASDAQ: NBIX), Novavax Inc. (NASDAQ: NVAX), and Novo Nordisk A/S (NYSE: NVO). All you have to do is sign up today for this free limited time offer by clicking the link below.
In the first quarter, Novo Nordisk’s (NVO) premix insulin generated net revenues of 2.64 billion Danish kroner compared to 2.86 billion Danish kroner in the first quarter of 2017, which reflected an ~8.0% YoY (year-over-year) decline.
Novo Nordisk’s (NVO) Tresiba reported revenues of 1.76 billion Danish kroner in the first quarter compared to 1.49 billion Danish kroner in the first quarter of 2017, which reflected ~18.0% YoY (year-over-year) growth.
In June, Novo Nordisk (NVO) presented the results of its Phase 3a PIONEER 1 trial. This trial demonstrated that oral semaglutide significantly decreased the blood sugar levels in individuals with type 2 diabetes compared to placebo therapy.
Novo Nordisk (NVO) reported revenues of 26.9 billion Danish kroner in the first quarter, compared to 28.5 billion Danish kroner in the first quarter of 2017, which reflected an ~5.0% year-over-year (or YoY) decline.
Biotech stocks came under pressure earlier in the week, weighed down by negative trial results, mixed FDA verdicts and overall pessimistic broader market sentiment, but recovered in the last two sessions. ...
EyePoint Pharmaceuticals, Inc. (EYPT), a specialty biopharmaceutical company developing and commercializing innovative ophthalmic products, today announced the appointment of Göran Ando, M.D., to the Company’s Board of Directors. Dr. Ando, the former Chairman of the Board of Novo Nordisk A/S (NVO), a global pharmaceutical company, brings more than 35 years of global drug development and general management experience to EyePoint. “Dr. Ando’s extensive experience across the many facets of the global pharmaceutical industry will undoubtedly be valuable as we transition into a commercial ophthalmic company with our planned U.S. launches of DEXYCU™ and, if approved, YUTIQ™,” said David J. Mazzo, Ph.D., Chairman of the Board of Directors of EyePoint Pharmaceuticals.
Novo Nordisk A/S said its diabetes treatment Tresiba showed “significantly improved” blood sugar control and lower rates of hypoglycemia compared with insulin glargine U300 in real-world evidence study....
Diabetes drugmaker Novo Nordisk presented a post-hoc analysis of the SUSTAIN 7 trial comparing treatment effect in body weight across baseline BMI subgroups receiving Novo's Ozempic or Eli Lilly's dulaglutide, ...
While the Trump administration touts its efforts to lower drug prices with its "blueprint," the debate over how drugs are priced and how high those prices are in the U.S. picks up speed. Patient groups elected officials and the American Medical Association are now calling on drug companies to explain how they arrive their prices for insulin. Part of the challenge for diabetics is that there is no generic form of insulin on the U.S. market.
Roche (RHHBY) will buy the remaining stake in Foundation Medicine for $2.4 billion. PTC Therapeutics (PTCT) presents encouraging preliminary data from an early-stage study in spinal muscular atrophy.
is riding the success of its experimental diabetes drug's positive test results, with the shares rising 1.65% Thursday to $46.40. The stock has been rising on a successful test that pitted Novo's oral semaglutide drug against the DDP-4 inhibitor Januvia from Merck & Co. and another Novo drug called Victoza, a once-a-week injectable pen used to regulate blood-sugar levels.
Novo Nordisk (NVO) announces positive headline results of two phase III studies PIONEER oral formulation of Ozempic (semaglutide) as a treatment for adults with type II diabetes.
Novo Nordisk A/S is having one of its best days in more than two months, with shares popping 2.58% -- their highest percentage gain since May 2 -- shortly after the market opened Thursday. NOV added $1.
Novo Nordisk (NVO) enters into a research collaboration and option agreement with Kallyope, Inc. to develop novel therapies for diabetes and obesity.
Several big pharma companies are about to lose patent exclusivity for blockbuster drugs. Should investors be worried?
Shares in Novo Nordisk (NOVOb.CO) opened down 4 percent on Friday after a media report citing anonymous sources said the world's biggest diabetes drug company mulls axing up to 3,000 staff and dropping its long-term financial targets. Denmark's Novo Nordisk said in May that the new rules would cut its 2019 sales by 1-2 percent but kept its long-term operating growth forecast of 5 percent. According to Danish daily Borsen, the firm is now considering ditching the long-term target due to "uncertain and unpredictable markets".